MIR136

Summary

MIR136 (microRNA 136, HGNC:31522) is a microRNA gene on chromosome 14q32.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406927 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31522
Approved symbol	MIR136
Name	microRNA 136
Location	14q32.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-136
Ensembl gene	ENSG00000207942
Ensembl biotype	miRNA
OMIM	611710
Entrez	406927
RNAcentral	URS00002130B2 — miRNA, 82 nt, 26 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385207

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385207 — 1 exons

Exon	Start	End
ENSE00001500213	100884702	100884783

Expression profiles

Bgee: expression breadth broad, 11 present calls, max score 81.32.

Top tissues by expression

11 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	81.32	gold quality
amygdala	UBERON:0001876	65.24	gold quality
renal glomerulus	UBERON:0000074	63.92	gold quality
cerebellar hemisphere	UBERON:0002245	58.17	gold quality
brain	UBERON:0000955	58.05	gold quality
ovary	UBERON:0000992	55.75	silver quality
pituitary gland	UBERON:0000007	54.30	silver quality
prostate gland	UBERON:0002367	54.22	gold quality
islet of Langerhans	UBERON:0000006	51.59	silver quality
midbrain	UBERON:0001891	50.05	gold quality
substantia nigra	UBERON:0002038	50.05	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• miR-136 might play a tumor-suppressive role in human glioma (PMID:22967897)
• miR-136 promotes Erk1/2 phosphorylation through targeting PPP2R2A in NSCLC cells and suggest that it may serve as a therapeutic target in NSCLC therapy. (PMID:23959478)
• Hsa-mir-93, hsa-mir-17, hsa-mir-22*, hsa-mir-126*, hsa-mir-142-3p, hsa-mir-144*, hsa-mir-486-5p, hsa-mir-451, and hsa-mir-92a were up-regulated and hsa-mir-30a, hsa-mir-382, and hsa-mir-136 were down-regulated in bromocriptine-resistant prolactinomas (PMID:25064468)
• Loss of miR-136 expression is associated with cisplatin resistance and glioma. (PMID:25139024)
• miR-136 may play a tumor-suppressive role by repressing EMT and prometastatic traits via targeting Smad2 and Smad3. (PMID:25198664)
• MiR-136 plays a key role in temozolomide (TMZ) resistance by targeting AEG-1 in glioma cell line, suggesting that miR-136 can be used to predict a patient’s response to TMZ therapy as well as serve as a novel potential maker for glioma therapy. (PMID:25266957)
• Findings suggest that miR-136 may function as an anti-oncogene and deficiency of miR-136 expression in ovarian cancer can induce chemoresistance at least in part by downregulating apoptosis and promoting the repair of cisplatin-induced DNA damage. (PMID:25482209)
• miR-136 may play an important role during TGF-beta1-induced proliferation arrest by targeting PPP2R2A in keratinocytes. (PMID:25654102)
• microRNA-136 is a positive regulator of myeloid differentiation, inducing higher levels of CD11b, CD14, C/EBPepsilon, cytokines, reactive oxygen species and H(2)O(2), but degrading differentiation-associated molecules like NFIA. TNF-alpha increases mir-136. (PMID:26329426)
• Data show that microRNA-136 (miRNA-136) antagonized H5N1 influenza A virus replication, and as an interleukin 6 (IL-6) repressor, simultaneously as an immune trigger of retinoic acid-inducible gene 1 (RIG-I) signaling. (PMID:26450567)
• these results demonstrated that miRNA-136 was a key anti-invasive miRNA and further confirmed the oncogenic role of RASAL2 in triple-negative breast cancer. (PMID:27108696)
• Data suggest that DNA is differentially methylated (hypomethylated) at a gene locus associated with regulation of expression of RTL1 and miR136 in type 1 diabetes; these studies were conducted using tissue bank placentas and whole blood cell DNA from children with type 1 diabetes. (RTL1 = retrotransposon-like protein 1; miR136 = microRNA 136) (PMID:27174469)
• MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3 pathway. (PMID:27887917)
• High level of miR-136 could suppress cell proliferation and promote apoptosis of mesenchymal stem cells through targeting BCL2. It could also impairs HUVEC capillary formation by suppressing VEGF (PMID:28161054)
• Furthermore, our results showed that ectopic expression of HOXC10 could reverse inhibition of metastasis by overexpressed miR-136 in GC-9811P cells. Our findings provide new insights into the role of miR-136 in the gastric cancer-specific peritoneal metastasis and implicate the potential application of miR-136 in gastric cancer peritoneal metastasis therapy. (PMID:28656883)
• the expression and function of miR-136 in colon cancer and the potential underlying mechanism; Liver receptor homolog-1 was identified as a direct target gene of miR-136 (PMID:28710032)
• Polymorphisms in IL18RAP influence susceptibility to obesity. We demonstrated that the A allele in rs7559479 increases MIR136 binding, which regulates IL-18 system activity. (PMID:29146643)
• Low miR136 expression is associated with Hepatocellular Carcinoma. (PMID:29295728)
• t can be concluded that miR-136 enhances inflammatory damage probably by targeting klotho as has been observed in luciferase assay by inactivation of JAK/STAT and mTOR signaling pathways. (PMID:29441871)
• MiR-136-5p is overexpressed in lung adenocarcinoma and is involved in the molecular mechanism of lung adenocarcinoma via suppressing the expressions of downstream targets (PMID:29526559)
• Findings provide the first evidence that the aberrant expression of miR-136 may be implicated into carcinogenesis and cancer progression of OS. Functionally, miR-136 may inhibit the proliferation, migration and invasion of OS cells via negatively regulating its target gene MTDH. (PMID:29562498)
• Downregulated miR-136-5p may target UGT1A7 and ADH7 and participate in ascorbate and aldarate metabolism, pentose and glucuronate interconversions, and retinol metabolism (PMID:29650443)
• mir-136 is regulated by circular RNA hsa_circ_0023404 in the cervical cancer. (PMID:29738762)
• Role of mesenchymal stem cells exosomes derived microRNAs; miR-136, miR-494 and miR-495 in pre-eclampsia diagnosis and evaluation (PMID:30261165)
• Hsa_circ_0136666 promotes the proliferation and invasion of colorectal cancer through miR-136/SH2B1 axis. (PMID:30370521)
• miR-136 promotes apoptosis in gastric cancer cells by targeting AEG-1 and BCL2 expression. (PMID:30468468)
• Long noncoding RNA DSCAM-AS1 is associated with poor clinical prognosis and contributes to melanoma development by sponging miR-136. (PMID:31002140)
• Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136. (PMID:31069828)
• Up-regulation of miR-136 reduced the survival rate, suppressed colony formation ability and induced apoptosis of esophageal squamous cell carcinoma (ESCC) cells under irradiation, which was reversed by upregulated mucin 1 (MUC1). (PMID:31247211)
• Overexpressed miR-136 attenuates angiogenesis and enhances cell apoptosis in gallbladder cancer via the JNK signaling pathway by downregulating the expression of MAP2K4. (PMID:31369289)
• CircTIMELESS regulates the proliferation and invasion of lung squamous cell carcinoma cells via the miR-136-5p/ROCK1 axis. (PMID:31960961)
• Circ_PUM1 promotes the development of endometrial cancer by targeting the miR-136/NOTCH3 pathway. (PMID:32073729)
• Knockdown of hsa_circ_0118530 repressed polycystic ovary syndrome progression via sponging miR-136. (PMID:32220601)
• data identified that the promotion of gastric cancer (GC) growth and metastasis induced by circRNA_100876 interacted with miR-136 and MIEN1, indicating an emerging announcement for uncovering the potential mechanism of GC progression (PMID:32305633)
• CRNDE mediates the viability and epithelial-mesenchymal transition of renal cell carcinoma via miR-136-5p. (PMID:32808846)
• MicroRNA-136-5p regulates gemcitabine resistance in pancreatic cancer via down-regulating ZNF32. (PMID:33155203)
• Downregulation of interleukin-6 and C-reactive protein underlies a novel inhibitory role of microRNA-136-5p in acute lower extremity deep vein thrombosis. (PMID:33188660)
• Correlation between serum microRNA-136 levels and RAAS biochemical markers in patients with essential hypertension. (PMID:33275245)
• Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis. (PMID:33288752)
• Circ_0003998 Regulates the Progression and Docetaxel Sensitivity of DTX-Resistant Non-Small Cell Lung Cancer Cells by the miR-136-5p/CORO1C Axis. (PMID:33511909)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
rattus_norvegicus	Mir136	ENSRNOG00000036493

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.